Chemical inactivation of recombinant vaccinia viruses and the effects on antigenicity and immunogenicity of recombinant simian immunodeficiency virus envelope glycoproteins

Vaccine

Volumn 15, Issue 17-18, 1997, Pages 1839-1845

  Hulskotte, Ellen G J ^a,b   Dings, Marlinda E M ^a,b   Norley, Stephen G ^c   Osterhaus, Albert D M E ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Paraformaldehyde; SIV; Vaccinia virus

Indexed keywords

AZIRIDINE; INACTIVATED VACCINE; PARAFORMALDEHYDE; RECOMBINANT PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; CELL STRAIN BHK; FEMALE; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIRUS INACTIVATION;

ANIMALS; AZIRIDINES; CRICETINAE; FIXATIVES; FORMALDEHYDE; GENE PRODUCTS, ENV; POLYMERS; RATS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0030733909     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00131-X     Document Type: Article

References (30)

1. Moss, B. Poxviruses: The viruses and their replication. In: Virology (Eds Fields, B.N., Knipe, D.M. and Howley, P.M.). Lippincott-Raven Publishers, Philadelphia, 1996, pp. 2637-2673.
2. Brown, F. Review of accidents caused by incomplete inactivation of viruses. In: Virological Safety Aspects of Plasma Derivatives (Ed. Brown, F.). Dev. Biol. Standard, 1993, Vol. 81, pp. 103-107.
3. Moore, J.P., Jameson, B., Weiss, R.A. and Sattentau, Q.J. The HIV-cell fusion reaction. In: Viral Fusion Mechanisms (Ed. Bentz, J.). CRC Press, Boca Raton, 1992, pp 233-289.
4. Ferguson, M., Wood, D.J. and Minor, P.D. Antigenic structure of poliovirus in inactivated vaccines. J. Gen. Virol. 1993, 74, 685-690.
5. King, D.J. Evaluation of different methods of inactivation of Newcastle disease virus and avian influenza virus in egg fluids and serum. Avian Dis. 1991, 35, 505-514.
6. Babcock, G.F. and Dawes, S.M. Immunophenotyping using fixed cells. Methods Cell Biol. 1994, 41, 81-93.
7. + T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS 1993, 7, 781-786.
8. Hu, S. and Caldwell, H.D. Kinetics of chlamydial antigen processing and presentation to T cells by paraformaldehyde fixed murine bone marrow derived macrophages. Infect. Immun. 1995, 63, 946-953.
9. + cytotoxic T lymphocyte responses in cynomolgus macaques infected with SIVmac32H(J5): quantitative analysis by in vitro stimulation. Vaccine (in press)
10. Bahnemann, H.G. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 1990, 8, 299-303.
11. Rimmelzwaan, G.F., Siebelink, K.H.J., Huisman, R.C., Moss, B. and Osterhaus, A.D.M.E. Removal of the cleavage site of recombinant FIV envelope protein facilitates incorporation of the surface glycoprotein in immune stimulating complexes. J. Gen. Virol. 1994, 75, 2097-2102.
12. Hulskotte, E.G.J., Rimmelzwaan, G.F. and Boes, J. et al. Antigenicity and immunogenicity of recombinant envelope glycoproteins of SIVmac32H with different in vivo passage histories. Vaccine 1995, 13, 1187-1197.
13. Kent, K.A., Gritz, L. and Stallard, G. et al. Production and characterization of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. AIDS 1991, 5, 829-836.
14. Kent, K.A., Rud, E. and Corcoran, T. et al. Identification of two neutralizing and eight non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res. Human Retrovir. 1992, 8, 1147-1151.
15. Doyle, C.B., Bhattacharyya, U., Kent, K.A., Stott, J.E. and Jones, I.M. Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virus. J. Virol. 1995, 69, 1257-1260.
16. Kent, K.A. Neutralising epitopes of simian immunodeficiency virus envelope glycoprotein. J. Med. Primatol. 1995, 24, 145-149.
17. Javaherian, K., Zuchowsiki, L. and Clark, F.T. Alanine substitution of two arginines in amino terminus of V3 of SIV disrupts CD4 binding whereas a similar replacement of two amino acids, lysine and arginine, in the carboxyl half of V3 prevents binding of a neutralizing monoclonal antibody. AIDS Res. Human Retrovir. 1995, 11, 1101-1105.
18. De Vries, P., Heeney, J.L. and Boes, J. et al. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 1994, 12, 1443-1452.
19. Murphy, B.R. and Chanock, R.M. Immunization against viruses. In: Virology, 2nd Edn, Vol. 1 (Eds Fields, B.N., Knipe, D.M., Chanock, R.M. et al.). Raven Press, New York, 1990, pp. 469-502.
20. Wesslén, T., Lycke, E. and Olin, G. Inactivation of poliomyelitis virus by formaldehyde. Arch. Ges. Virusf. 1957, 7, 394-401.
21. Gard, S. and Lycke, E. Inactivation of poliovirus by formaldehyde. Analysis of inactivation curves. Arch. Ges. Virusf. 1957, 7, 471-493.
22. Graves, J.H. Formaldehyde inactivation of foot-and-mouth disease virus as applied to vaccine preparation. Am. J. Vet. Res. 1963, 24, 1131-1135.
23. Schultz, P., Rightsel, W.A., Timm, E.A., Taylor, A.R. and McLena, W. Jr. Partially inactivated poliomyelitis virus: initiation of infection in tissue cultures. J. Immunol. 1957, 79, 497-507.
24. Böttiger, M., Lycke, E., Melén, B. and Wrange, G. Inactivation of poliomyelitis virus by formaldehyde. Incubation time in tissue culture of formalin treated virus. Arch. Ges. Virusf. 1958, 8, 259-266.
25. Darling, A.J. Considerations in performing virus spiking experiments and process validation studies. In: Virological Safety Aspects of Plasma Derivatives, Vol. 81 (Ed. Brown, F.). Dev. Biol. Standard, 1993, pp. 221-229.
26. Hulskotte, E.G.J., Geretti, A.M. and Siebelink, K.H.J. et al. Vaccine-induced virus neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H(J5). J. Virol. 1995, 69, 6289-6296.
27. Javaherian, K., Langlois, A.J. and Schmidt, S. et al. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1992, 89, 1418-1422.
28. Thali, M., Furman, N. and Ho, D.D. et al. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 1992, 66, 5635-5641.
29. Profy, A.T., Salinas, P.A., Eckler, L.I., Dunlop, N.M., Nara, P.L. and Putney, S.D. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J. Immunol. 1990, 144, 4641-4647.
30. Sattentau, Q.J. Conservation of HIV-1 gp120 neutralizing epitopes after formalin inactivation. AIDS 1995, 9, 1383-1385.